Gedeon Richter Media Richter publishes Q1 2026 results
Richter publishes Q1 2026 results
12/05/2026
An eventful quarter; guidance reiterated
  • CER Pharma revenues grew by 5.9%, driven by Vraylar® and BIO, while reported Pharma revenues declined by 1.3% YoY to HUF 217bn in Q1 2026, implying more than 7ppt currency headwind.
  • CER Clean EBIT (pharma) growth was 15%, supported by company-wide long-term cost management efforts (lower opex) and some milestone income; reported Clean EBIT (pharma) grew by only 1.5% to HUF 69.7bn.
  • Net profit was HUF 65.3bn in Q1 2026, down by 4% YoY, on smaller net financial income than a year ago. Free Cash Flow generation remained robust at HUF 77bn, up 29% YoY.
  • 2026 guidance is fully reiterated: high-single-digit growth in both revenues and Clean EBIT (at constant exchange rates).

 

Budapest, 12 May 2026 - Gedeon Richter Plc. (“Richter”) announced today its Q1 2026 financial results.

CER (constant exchange rate) Pharma revenues grew by 5.9% in Q1 2026, slightly below the high-single-digit growth guidance for the full year, mostly due to timing of some deliveries. FX was a major drag on reported revenues, representing more than 7ppt headwind (due to the weak USD and stronger HUF). Hence, reported Pharma revenues declined by 1.3% YoY to HUF 217bn in Q1 2026.   

  • CNS revenues increased by 4% in Q1 2026 YoY, as currency movements mostly offset another spectacular performance from Vraylar® (AbbVie’s net sales increased by 18% to USD 905mn). Reagila® sales were down slightly YoY, as strong in-market sales growth was offset by the timing of deliveries.
  • Women’s Healthcare sales growth (+6% CER) was affected by the timing of shipments (some contraception sales in APAC likely to be realized later this year; some pre-shipments affected EEU/CEU revenues). The underlying strength of the leading products (Drovelis®, Ryeqo®, Lenzetto®, Bemfola® and Evra®) remains intact.
  • BIO revenues jumped in Q1 (+35% CER), driven by bouncing teriparatide revenues from a low base and new product sales.
  • GenMed revenues fell by 8.5% in Q1 YoY (CER) due to lack of flu season (weak OTC), portfolio streamlining, trade-related financial headwinds and distributor stock phasing in some markets.

Gross profit (pharma) fell by 4.7% YoY to HUF 147bn in Q1 2026; gross margin declined to 67.6% (-2.4ppt).

CER Clean EBIT (pharma) growth was 15%, driven by CNS and BIO, and supported by company-wide long-term cost management efforts (lower opex) and some milestone income. Reported Clean EBIT (pharma) grew by only 1.5% to HUF 69.7bn due to the FX headwind.

Reported EBIT stood at HUF 67.4bn in Q1 2026, nearly unchanged compared to the previous year.

Net profit (attributable to the owners of the parent) was HUF 65.3bn in Q1 2026, declining by 4% YoY, as a result of flat operating profit and smaller net financial income than a year ago.

Free cash flow (before M&A) was at HUF 77bn in Q1 2026, up 29% YoY, on the back of stronger operating cash flows and no increase in Net Working Capital funding need.

 

Gábor Orbán, CEO commented the results:

“An eventful Q1 is behind us and we are confident we are on the right track to deliver our high-single-digit (CER) growth targets in 2026. We are very excited about the upcoming launch and market potential of Fylrevy®, the first hormonal innovation in menopause in decades, our new biosimilar products’ contribution to further narrowing the gap to profitability in BIO and our joint R&D projects with AbbVie. Revenues were slightly behind plan in the first quarter in Women’s Healthcare, primarily due to timing of deliveries, and also in GenMed on multiple external and internal headwinds, which was not fully offset by the continued spectacular performance of Vraylar® and strong BIO revenues. Clean EBIT growth was above plan reflecting some milestone income and the benefit of our long-term cost management efforts. Currency trends continue to weigh on our reported financials, while some visible positive shift in country risk premium and bond yields is taking place in Hungary.”

 

About Gedeon Richter Plc.

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.8bn and sales of EUR 2.3bn in 2025, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com

 

For further information:

Investors:        Róbert Réthy, CFA                                                                +36 20 342 2555

Media:              Zsuzsa Beke                                                                            +36 20 916 4507